miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression
JCI Insight · 08.10.2024 · 9 (19)
DOI: 10.1172/jci.insight.168476 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 27.08.2024. Verfasst von Pablo Fernández-Tussy und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Biology and Therapeutics Program. Hauptthemen laut MEDLINE: MicroRNAs, Hepatocytes, Carcinoma, Hepatocellular, Disease Progression. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
The complexity of the mechanisms underlying metabolic dysfunction–associated steatotic liver disease (MASLD) progression remains a significant challenge for the development of effective therapeutics. miRNAs have shown great promise as regulators of biological processes and as therapeutic targets for complex diseases. Here, we study the role of hepatic miR-33, an important regulator of lipid metabolism, during the progression of MASLD and the development of hepatocellular carcinoma (HCC). We report that miR-33 was elevated in the livers of humans and mice with MASLD and that its deletion in hepatocytes (miR-33 HKO ) improved multiple aspects of the disease, including steatosis and inflammation, limiting the progression to metabolic dysfunction–associated steatotic hepatitis (MASH), fibrosis, and HCC. Mechanistically, hepatic miR-33 deletion reduced lipid synthesis and promoted mitochondrial fatty acid oxidation, reducing lipid burden. Additionally, absence of miR-33 altered the expression of several known miR-33 target genes involved in metabolism and resulted in improved mitochondrial function and reduced oxidative stress. The reduction in lipid accumulation and liver injury resulted in decreased YAP/TAZ pathway activation, which may be involved in the reduced HCC progression in HKO livers. Together, these results suggest suppressing hepatic miR-33 may be an effective therapeutic approach to temper the development of MASLD, MASH, and HCC in obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Biology and Therapeutics Program.
- Department of Comparative Medicine.
- Yale Center for Molecular and System Metabolism, and.
- Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
- Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland, USA.
- Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NCATS NIH HHS
- NHBLI
- NIDDK
- American Heart Association
Zitieren
APA
Fernández-Tussy, P., Cardelo, M. P., Zhang, H., Sun, J., Price, N. L., Boutagy, N. E., Goedeke, L., Cadena-Sandoval, M., Xirouchaki, C. E., Brown, W., Yang, X., Pastor-Rojo, O., Haeusler, R. A., Bennett, A. M., Tiganis, T., Suárez, Y., & Fernández-Hernando, C. (2024). miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression. JCI Insight, 9(19). https://doi.org/10.1172/jci.insight.168476
Vancouver
Fernández-Tussy P, Cardelo MP, Zhang H, Sun J, Price NL, Boutagy NE, et al. miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression. JCI Insight. 2024;9(19). doi:10.1172/jci.insight.168476
BibTeX
@article{FernndezTussy2024,
author = {Fernández-Tussy, Pablo and Cardelo, Magdalena P and Zhang, Hanming and Sun, Jonathan and Price, Nathan L and Boutagy, Nabil E and Goedeke, Leigh and Cadena-Sandoval, Martí and Xirouchaki, Chrysovalantou E and Brown, Wendy and Yang, Xiaoyong and Pastor-Rojo, Oscar and Haeusler, Rebecca A and Bennett, Anton M and Tiganis, Tony and Suárez, Yajaira and Fernández-Hernando, Carlos},
title = {miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression},
journal = {JCI Insight},
year = {2024},
volume = {9},
number = {19},
doi = {10.1172/jci.insight.168476}
}
EUVIMED